| Bioactivity | Nimacimab (RYI-018) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases[1][2]. |
| Name | Nimacimab |
| CAS | 2098636-09-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Priyadarshini Loganathan, et al. Current and future treatment management strategies for gastroparesis. Expert Review of Endocrinology & Metabolism 16:2, pages 25-35. [2]. Dao M, et al. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. Front Endocrinol (Lausanne). 2021 Jul 7;12:720734. |